

Gowling Lafleur Henderson LLP | Barristers &amp; Solicitors | Patent &amp; Trade Mark Agents |

**GOWLINGS**

1 Place Ville Marie  
37<sup>th</sup> Floor  
Montréal, Québec  
Canada H3B 3P4  
Tel 514 878-9641  
Fax 514 878-1450  
www.gowlings.com

## Facsimile

To  
Company United States Patent and Trademark Office  
Fax Number (571) 273-8300  
Telephone Number

From Philip Swain  
Telephone Number (514) 392-9562  
Date May 24, 2007  
Re U.S. Patent application no. 10/559,675  
Total Pages 8 (including cover)  
File Number L80003400US  
CopyTrak # 4011

**RECEIVED  
CENTRAL FAX CENTER**

**MAY 24 2007**

**PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**APPLICANT** : James B. Jaquith et al.  
**TITLE** : ACYLATED AND NON-ACYLATED IMIDAZO[2,1-B]-  
1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES  
THEREOF  
**FILED** : December 6, 2005  
**SERIAL NO.** : 10/559,675  
**ATTORNEY DOCKET NO.** : L80003400US  
**CUSTOMER NO.** : 49580

**STATUS ENQUIRY**

If there is a problem with transmission or all pages are not received, please call us at the number indicated above. This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (call us collect), and return the original to us by postal service at the address noted above. Thank you.

Montréal | Ottawa | Toronto | Hamilton | Waterloo Region | Calgary | Vancouver | Moscow |

RECEIVED  
CENTRAL FAX CENTER

002/008

MAY 24 2007

## Certificate of Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on: May 24, 2007

BRUNO CORNIL  
Printed name of person transmitting correspondence

BCL  
Signature of person transmitting correspondence

## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : James B. Jaquith et al.  
TITLE : ACYLATED AND NON-ACYLATED IMIDAZO[2,1-B]-  
1,3,4,-THIADIAZOLE-2-SULFONAMIDES, AND USES  
THEREOF  
FILED : December 6, 2005  
SERIAL NO. : 10/559,675  
ATTORNEY DOCKET NO. : L80003400US  
CUSTOMER NO. : 49580

Montreal, Quebec, Canada  
May 24, 2007

## STATUS INQUIRY

Sir:

With reference to the above-captioned application, it is believed that all completion requirements have been satisfied. This is evidenced by a Notice of Acceptance of Application under 35 U.S.C. 371 and 37 CFR 1.495, mailed by the Office on March 9, 2006, a copy of which is enclosed herewith. Furthermore, a Filing Receipt mailed by the Office on March 9, 2006 provides a projected publication date of June 15, 2006.

To the knowledge of the Applicant's agent of record, the application has not yet published.

It is respectfully requested that the Office send a Notice of Publication to the attention of the undersigned agent or an estimate as to when the application will be published.

Respectfully submitted,

**GOWLING LAFLEUR HENDERSON LLP**



Date: May 24, 2007

Philip Swain, Ph.D.  
Reg. No. 55,978  
1 Place Ville-Marie, 37th Floor  
Montreal, Quebec H3B 3P4  
CANADA

Tel.: (514) 392-9562  
Fax: (514) 878-1450

Docket No. L80003400US

**RECEIVED  
CENTRAL FAX CENTER**

**MAY 24 2007**

Page 1 of 2



**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1430  
Alexandria, Virginia 22313-1460  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/559,675	James B. Jaquith	130-PCT-US
		INTERNATIONAL APPLICATION NO.
		PCT/CA04/00873
		I.A. FILING DATE
		PRIORITY DATE
		06/14/2004
		06/13/2003

49580  
AEGERA THERAPEUTICS INC.

49580  
AEGERA THERAPEUTICS INC.  
810 CHEMIN DU GOLF  
VERDUN, QC H3E-1A8  
CANADA

**CONFIRMATION NO. 5928**

### 371 ACCEPTANCE LETTER

\*OC00000016191955\*

**Date Mailed: 03/09/2006**

**NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495**

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

<u>12/06/2005</u>	<u>12/06/2005</u>
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS	DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

**The following items have been received:**

- Indication of Small Entity Status
- Copy of the International Application filed on 12/06/2005
- Copy of the International Search Report filed on 12/06/2005
- Preliminary Amendments filed on 12/08/2005
- Information Disclosure Statements filed on 12/08/2005
- Oath or Declaration filed on 12/08/2005
- Request for Immediate Examination filed on 12/08/2005
- U.S. Basic National Fee filed on 12/08/2005
- Priority Documents filed on 12/08/2005

Page 2 of 2

---

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

---

INDIA L EVANS

Telephone: (703) 308-9140 EXT 212

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)

**RECEIVED**  
CENTRAL FAX CENTER

MAY 24 2007

Page 1 of 3



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO	FILING OR 371 (c) DATE	ART UNIT	FILED REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/559,675	12/08/2005	1615	1175	130-PCT-US	1	46	4

49580  
AEGERA THERAPEUTICS INC.  
810 CHEMIN DU GOLF  
VERDUN, QC H3E-1A8  
CANADA

CONFIRMATION NO. 5928

FILING RECEIPT



"0000000018191867"

Date Mailed: 03/09/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

James B. Jaquith, Pincourt, CANADA;  
John W. Gillard, Bate D'Urfe, CANADA;

**Power of Attorney:** The patent practitioners associated with Customer Number 49580.

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/CA04/00873 06/14/2004  
which claims benefit of 60/477,967 08/13/2003

**Foreign Applications**

**If Required, Foreign Filing License Granted:** 03/03/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/559,675**

**Projected Publication Date:** 06/15/2006

**Non-Publication Request:** No

**Early Publication Request:** No

**\*\* SMALL ENTITY \*\***

**Title**

Acylated and non-acylated imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides, and uses thereof

**Preliminary Class**

424

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stoptakes.gov>. Part of a Department of Commerce Initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time. If the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12. If a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).